Rhabdomyosarcoma

Score 4.6 = 4.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07169344 · Oslo University Hospital · Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
• Ph2NCT07173972 · Oslo University Hospital · Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Score 4.2 = 4.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT07466316 · Children's Oncology Group · A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
• Ph1/Ph2NCT04890093 · National Cancer Institute (NCI) · Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07819838 · Children's Oncology Group · Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07830667 · Children's Oncology Group · A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06625190 · University of Florida · Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Score 1.7 = 1.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06721689 · Theodore Laetsch · PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06709495 · David S Shulman, MD · Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Score 1.5 = 0 leading Phase 2+ trials + 1.5 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07169344 · Oslo University Hospital · Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
• Ph2NCT07173972 · Oslo University Hospital · Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06541262 · Milton S. Hershey Medical Center · Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06683846 · Fudan University · Ivonescimab in the Treatment of Multiple Advanced Tumors

Score 1.5 = 0 leading Phase 2+ trials + 1.5 other trial roles + 0 talks + 0 posters. 0 of 2 trials are Phase 2+.

• Ph1NCT07148050 · Seattle Children's Hospital · Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
• Ph1NCT07224568 · Seattle Children's Hospital · Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

Score 1.5 = 0 leading Phase 2+ trials + 1.5 other trial roles + 0 talks + 0 posters. 0 of 2 trials are Phase 2+.

• Ph1NCT07148050 · Seattle Children's Hospital · Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
• Ph1NCT07224568 · Seattle Children's Hospital · Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06023641 · St. Jude Children's Research Hospital · Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06239272 · St. Jude Children's Research Hospital · NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06277154 · HRYZ Biotech Co. · MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Score 1.2 = 1.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06277154 · HRYZ Biotech Co. · MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Score 1.2 = 0 leading Phase 2+ trials + 1.2 other trial roles + 0 talks + 0 posters. 0 of 3 trials are Phase 2+.

• Ph1NCT04715191 · Baylor College of Medicine · Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
• Ph1NCT04377932 · Baylor College of Medicine · Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
• Ph1NCT06198296 · Baylor College of Medicine · Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Score 1.1 = 1.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05457829 · Sun Yat-sen University · Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06094101 · University Hospital Tuebingen · Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

Score 0.9 = 0.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT04796012 · University of Texas Southwestern Medical Center · VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Score 0.8 = 0.1 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT06865664 · National Cancer Institute (NCI) · FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
• Ph2NCT02867592 · National Cancer Institute (NCI) · Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07172958 · Children's National Research Institute · Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07172958 · Children's National Research Institute · Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07222735 · St. Jude Children's Research Hospital · Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT05304585 · Children's Oncology Group · Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05135975 · Nationwide Children's Hospital · A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT06441331 · ITM Solucin GmbH · Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Score 0.6 = 0.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT05071209 · National Cancer Institute (NCI) · Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Score 0.6 = 0 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT06198296 · Baylor College of Medicine · Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Score 0.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT04901702 · St. Jude Children's Research Hospital · Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Score 0.5 = 0.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT04994132 · Children's Oncology Group · A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT04320888 · National Cancer Institute (NCI) · Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT04284774 · National Cancer Institute (NCI) · Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Score 0.4 = 0.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT04388839 · H. Lee Moffitt Cancer Center and Research Institute · Evolutionary Therapy for Rhabdomyosarcoma

Score 0.3 = 0.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT04195555 · National Cancer Institute (NCI) · Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT05857969 · Florida International University · Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT05857969 · Florida International University · Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Score 0.3 = 0 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT05210374 · Case Comprehensive Cancer Center · Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT03210714 · National Cancer Institute (NCI) · Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Score 0.2 = 0.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT03698994 · National Cancer Institute (NCI) · Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)